

Rachel Burga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2492850/publications.pdf>

Version: 2024-02-01

15
papers

1,177
citations

623734

14
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

2067
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of 4-1BBL+ B cells with CD40 agonism and IFN γ elicits potent immunity against glioblastoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	42
2	PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function. <i>Nano Research</i> , 2020, 13, 736-744.	10.4	17
3	Engineering the TGF β Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 4400-4412.	7.0	52
4	Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 196.	2.8	44
5	Designing Magnetically Responsive Biohybrids Composed of Cord Blood-Derived Natural Killer Cells and Iron Oxide Nanoparticles. <i>Bioconjugate Chemistry</i> , 2019, 30, 552-560.	3.6	24
6	Cord blood natural killer cells expressing a dominant negative TGF β receptor: Implications for adoptive immunotherapy for glioblastoma. <i>Cytotherapy</i> , 2017, 19, 408-418.	0.7	97
7	Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 771-781.	3.3	122
8	Composite iron oxide–Prussian blue nanoparticles for magnetically guided T&sub>1&sub>-weighted magnetic resonance imaging and photothermal therapy of tumors. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6413-6424.	6.7	28
9	Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. <i>Cytotherapy</i> , 2016, 18, 1410-1421.	0.7	26
10	Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 817-829.	4.2	184
11	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor"Modified T-cell Therapy for CEA+ Liver Metastases. <i>Clinical Cancer Research</i> , 2015, 21, 3149-3159.	7.0	324
12	Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. <i>Cancer Gene Therapy</i> , 2014, 21, 457-462.	4.6	35
13	Liver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+CD11b+ myeloid cells. <i>Journal of Leukocyte Biology</i> , 2014, 96, 883-894.	3.3	14
14	Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils. <i>Journal of Leukocyte Biology</i> , 2013, 94, 813-823.	3.3	33
15	A functional agarose-hydroxyapatite scaffold for osteochondral interface regeneration. <i>Biomaterials</i> , 2012, 33, 5247-5258.	11.4	135